Tesamorelin: What the Research Shows
Tesamorelin is a synthetic 44-amino acid analog of growth hormone-releasing hormone (GHRH), modified at the N-terminus to improve its stability compared to native GHRH. It works by activating GHRH receptors in the pituitary gland, stimulating the body’s own growth hormone production, which in turn drives IGF-1 synthesis in the liver. Tesamorelin is distinctive among GHRH analogs for having the largest, most rigorous clinical trial program of any compound in this class — including FDA approval for a specific indication.
Visceral Fat Reduction
The pivotal research on tesamorelin comes from a pooled analysis of two multicenter, double-blind, placebo-controlled Phase 3 trials, encompassing 806 HIV-positive patients with excess abdominal fat. Researchers found that 26 weeks of daily tesamorelin significantly reduced visceral adipose tissue (VAT) as measured by CT scan, with a treatment effect of -7.2% relative to placebo. Patients also saw significant improvements in body image measures, both self-reported and physician-rated, and mean IGF-1 levels rose substantially compared to placebo (Falutz et al., Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two Phase 3 trials, JCEM, 2010).
Durability and Long-Term Effects
The same trial program included a 26-week safety extension. Researchers found that patients who continued tesamorelin through week 52 maintained their visceral fat reduction (-17.5% from original baseline), along with sustained improvements in waist circumference, triglycerides, and cholesterol — while preserving subcutaneous fat, which distinguishes tesamorelin’s effect from more generalized fat-loss approaches. A related analysis of the same trial data found that visceral fat reduction was also associated with improved liver enzyme levels in patients with elevated baseline transaminases (Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV, 2017).
Modern-Era Validation
Because the original Phase 3 trials predated the widespread use of integrase inhibitors (now a mainstay of HIV treatment), more recent research has re-examined tesamorelin’s effects in patients on modern antiretroviral regimens. A study in patients on integrase-inhibitor-based therapy found a median 16% reduction in visceral fat over 12 months — closely matching the 15-18% effect size seen in the original Phase 3 trials — while remaining well-tolerated and without negatively affecting glycemic control (Efficacy and Safety of Tesamorelin in People with HIV on Integrase Inhibitors, 2024).
Proposed Mechanism
Research points to a fairly direct physiological pathway:
- Pituitary GHRH receptor activation, stimulating endogenous, pulsatile growth hormone release rather than introducing exogenous GH directly
- IGF-1-mediated downstream effects, driving the metabolic changes responsible for visceral fat reduction
- Selectivity for visceral over subcutaneous fat, a distinguishing feature observed consistently across the trial program, though the precise mechanism behind this selectivity is not fully established
Regulatory Status
Tesamorelin is FDA-approved (marketed as Egrifta) for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy — a narrow, specific indication rather than broad approval for weight loss or GH deficiency generally.
Explore our Tesamorelin research product:
View TesamorelinThis overview reflects published clinical trial research. Products offered by Core Molecular Solutions are intended for laboratory research purposes only and are not for human or veterinary use.